Literature DB >> 19675224

Highly efficient antiviral CD8+ T-cell induction by peptides coupled to the surfaces of liposomes.

Akira Takagi1, Masanori Matsui, Satoshi Ohno, Hongying Duan, Osamu Moriya, Nobuharu Kobayashi, Hiroshi Oda, Masahito Mori, Akiharu Kobayashi, Maiko Taneichi, Tetsuya Uchida, Toshitaka Akatsuka.   

Abstract

In previous studies, we have demonstrated that liposomes with differential lipid components display differential adjuvant effects when antigens (Ags) are chemically coupled to their surfaces. When ovalbumin was coupled to liposomes made by using unsaturated fatty acids, it was found to be presented not only to CD4(+) T cells but also to CD8(+) T cells and induced cytotoxic T lymphocytes (CTLs) which effectively eradicated the tumor from mice. In this study, we coupled liposomes to immunodominant CTL epitope peptides derived from lymphocytic choriomeningitis virus (LCMV) and evaluated its potency as an antiviral vaccine. The intramuscular immunization of mice with the peptide-liposome conjugates along with CpG resulted in the efficient induction of antiviral CD8(+) T-cell responses which conferred complete protection against not only LCMV Armstrong but also a highly virulent mutant strain, clone 13, that establishes persistent infections in immunocompetent mice. The intranasal vaccination induced mucosal immunity effective enough to protect mice from the virus challenge via the same route. Complete protection was achieved in mice even when the Ag dose was reduced to as low as 280 ng of liposomal peptide. This form of vaccination with a single CTL epitope induced Ag-specific memory CD8(+) T cells in the absence of CD4(+) T-cell help, which could be shown by the complete protection of CD4-knockout mice in 10 weeks as well as by the analysis of recall responses. Thus, surface-linked liposomal peptide might have a potential advantage for the induction of antiviral immunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19675224      PMCID: PMC2756846          DOI: 10.1128/CVI.00116-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  46 in total

1.  Cytotoxic T-cell memory without antigen.

Authors:  L L Lau; B D Jamieson; T Somasundaram; R Ahmed
Journal:  Nature       Date:  1994-06-23       Impact factor: 49.962

2.  Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection.

Authors:  L S Klavinskis; J L Whitton; M B Oldstone
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

3.  Vaccination to prevent persistent viral infection.

Authors:  M B Oldstone; A Tishon; M Eddleston; J C de la Torre; T McKee; J L Whitton
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

4.  DNA vaccination against persistent viral infection.

Authors:  L P Martins; L L Lau; M S Asano; R Ahmed
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

5.  Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus.

Authors:  M Matloubian; S R Kolhekar; T Somasundaram; R Ahmed
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Dissection of antiviral and immune regulatory functions of tumor necrosis factor receptors in a chronic lymphocytic choriomeningitis virus infection.

Authors:  M Suresh; Xiaoyan Gao; Christopher Fischer; Nicole E Miller; Kavita Tewari
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

7.  Organ-specific selection of viral variants during chronic infection.

Authors:  R Ahmed; M B Oldstone
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

8.  CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.

Authors:  Joseph C Sun; Matthew A Williams; Michael J Bevan
Journal:  Nat Immunol       Date:  2004-08-08       Impact factor: 25.606

9.  Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence.

Authors:  R Ahmed; A Salmi; L D Butler; J M Chiller; M B Oldstone
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

Review 10.  Nanotechnology in vaccine delivery.

Authors:  Laura J Peek; C Russell Middaugh; Cory Berkland
Journal:  Adv Drug Deliv Rev       Date:  2008-02-07       Impact factor: 15.470

View more
  9 in total

1.  Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens.

Authors:  Nijaporn Yanasarn; Brian R Sloat; Zhengrong Cui
Journal:  Mol Pharm       Date:  2011-06-07       Impact factor: 4.939

2.  Characterization of CD8+ T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine.

Authors:  Joshua M Walker; Hans-Peter Raué; Mark K Slifka
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

3.  Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine.

Authors:  Maryam Amidi; Markus de Raad; Daan J A Crommelin; Wim E Hennink; Enrico Mastrobattista
Journal:  Syst Synth Biol       Date:  2010-10-26

4.  An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines.

Authors:  Aiala Salvador; Manoli Igartua; Rosa Maria Hernández; José Luis Pedraz
Journal:  J Drug Deliv       Date:  2011-06-15

5.  Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo.

Authors:  Yutaka Horiuchi; Akira Takagi; Tetsuya Uchida; Toshitaka Akatsuka
Journal:  Oncol Rep       Date:  2015-09-21       Impact factor: 3.906

Review 6.  Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic.

Authors:  Wang Ziqi; Cui Kai; Ulrich Costabel; Zhang Xiaoju
Journal:  Exploration (Beijing)       Date:  2022-07-21

Review 7.  Peptide Vaccine: Progress and Challenges.

Authors:  Weidang Li; Medha D Joshi; Smita Singhania; Kyle H Ramsey; Ashlesh K Murthy
Journal:  Vaccines (Basel)       Date:  2014-07-02

Review 8.  Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation.

Authors:  Saborni Chattopadhyay; Jui-Yi Chen; Hui-Wen Chen; Che-Ming Jack Hu
Journal:  Nanotheranostics       Date:  2017-06-09

9.  Coupling to the surface of liposomes alters the immunogenicity of hepatitis C virus-derived peptides and confers sterile immunity.

Authors:  Akira Takagi; Nobuharu Kobayashi; Maiko Taneichi; Tetsuya Uchida; Toshitaka Akatsuka
Journal:  Biochem Biophys Res Commun       Date:  2012-11-15       Impact factor: 3.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.